Abstract
Introduction:
The coexistence of tuberculosis (TB) and type 2 diabetes mellitus (T2DM) represents a growing global health challenge, particularly in low- and middle-income countries where TB remains endemic and T2DM prevalence is rising. Patients with T2DM exhibit a threefold higher risk of developing active TB and frequently present with more severe disease, including increased bacillary burden, delayed culture conversion, and higher relapse rates. These outcomes reflect the complex immunometabolic interactions between the two conditions. MicroRNAs (miRNAs), small non-coding regulators of post-transcriptional gene expression, emerge as potential biomarkers capable of integrating immune and metabolic processes.
Methods:
we conducted a systematic review of studies published between 2011 and 2025 in PubMed and Google Scholar, following PRISMA 2020 guidelines. Only studies involving adult human samples were included. Dysregulated miRNAs were standardized using miRBase and analyzed with miRNet v2.0, miRTarBase v9.0, and DIANA-miRPath v3.0. Interaction networks were constructed in Cytoscape, and functional enrichment analyses were performed using ClusterProfiler and MSigDB to identify shared pathways and gene targets.
Results:
The analysis revealed a set of miRNAs altered in both TB and T2DM, including hsa-miR-21, hsa-miR-29a-3p, hsa-miR-125a-5p, hsa-miR-125b, hsa-miR-130b, hsa-miR-144, hsa-miR-155, hsa-miR-223, and hsa-miR-486. These miRNAs converge on central target genes such as STAT3, PTEN, BCL2, MYC, RAF1, EGFR, IRS1, SMAD4, FOXO3, GLUT4, AKT1, and CTNNB1, regulating pathways of insulin signaling, glucose metabolism, apoptosis, inflammation, and fibrosis.
Discussion:
Shared miRNAs act as molecular nodes linking immunity and metabolism, providing a framework for biomarker development in TB-T2DM comorbidity. Their regulatory convergence suggests potential applications in diagnosis, prognosis, and therapeutic innovation, particularly in vulnerable populations where both diseases intersect. These findings underscore the importance of integrating immunometabolic biomarkers into personalized medicine strategies to address the dual burden of TB and T2DM.
Introduction
Tuberculosis (TB) and type 2 diabetes mellitus (T2DM) represent two of the greatest public health challenges worldwide, due to their high prevalence in low- and middle-income countries (LMICs) and their substantial clinical and socioeconomic impact. TB, caused by Mycobacterium tuberculosis (Mtb), continues to be one of the leading causes of infectious morbidity and mortality globally, with more than 10 million new cases and 1.3 million deaths reported annually (). On the other hand, T2DM has reached epidemic proportions, with approximately 537 million adults (20–79 years) living with diabetes globally in 2021, projected to reach 643 million by 2030 and 783 million by 2045 (). The burden of both diseases is particularly high in LMICs, where TB is endemic.
The coexistence of TB and T2DM in a single patient presents significant clinical challenges. Patients with T2DM have a threefold increased risk of developing active TB, in addition to more severe clinical presentations, including higher bacillary burden, poor response or resistance to treatment, delayed culture conversion, and higher probability of relapse (, ). Hyperglycemia alters the function of macrophages and T lymphocytes, dysregulates cytokine production (often reducing proinflammatory mediators while increasing anti-inflammatory cytokines), and impairs the formation and maintenance of granulomas multicellular structures essential for infection control (). In this context, there is an urgent need to identify molecular biomarkers that reflect the convergence of immunological and metabolic processes in TB-T2DM comorbidity.
MicroRNAs (miRNAs) are key regulators of post-transcriptional gene expression involved in both TB and T2DM. These small non-coding molecules, approximately 22 nucleotides in length, modulate critical pathways such as lymphocyte differentiation, macrophage polarization, cytokine signaling, and cellular metabolism (). Altered miRNA expression profiles have been reported in multiple infectious and metabolic diseases, including TB and T2DM, suggesting a central role in shared pathophysiology (, ).
In TB, several miRNAs, such as hsa-miR-21, hsa-miR-29a, hsa-miR-223, and hsa-miR-155, have been associated with regulation of innate and adaptive immune responses. For example, hsa-miR-21 has been linked to suppression of Th1 responses, while hsa-miR-29a regulates expression of genes involved in cell adhesion and extracellular matrix remodeling (, ). hsa-miR-223 modulates FOXO3 expression, affecting apoptosis of infected macrophages (), and hsa-miR-155 is involved in regulation of macrophage polarization and cytokine production ().
In T2DM, miRNAs such as hsa-miR-144, hsa-miR-126, and hsa-miR-130b are linked to insulin resistance, pancreatic beta cell dysfunction, and microvascular complications. hsa-miR-144 decreases IRS1 expression, affecting insulin signaling () hsa-miR-126 is associated with vascular complications and diabetic retinopathy (), and hsa-miR-130b regulates processes of lipid metabolism and insulin secretion (, ). These altered expression profiles reflect the complexity of post-transcriptional regulation in T2DM and its impact on metabolic homeostasis.
Specific miRNAs are dysregulated in both pathologies and may act as common molecular nodes integrating immune and metabolic responses. Among them are hsa-miR-21, hsa-miR-29a, hsa-miR-223, hsa-miR-144, and hsa-miR-155, which are involved in both immunity against Mtb and regulation of insulin signaling and cellular metabolism. The identification of these shared miRNAs represents a fundamental finding suggesting the existence of convergent molecular mechanisms that could explain, at least partially, the increased susceptibility to TB observed in patients with diabetes (, ).
Despite growing evidence on the role of miRNAs in TB and T2DM, there is limited literature reporting miRNA activity in this comorbidity. To our knowledge, this is the first systematic review with comprehensive bioinformatic analysis to identify and characterize miRNAs shared between both diseases. By integrating data from reference databases such as miRNet, miRTarBase, and DIANA-miRPath, we constructed networks of miRNA-mRNA interactions that reflect convergent molecular mechanisms in both pathologies.
The specific aims of this study are to:
Identify miRNAs reported as dysregulated in pulmonary TB and T2DM in experimental studies with human samples.
Compare expression profiles to determine miRNAs shared between both pathologies.
Analyze miRNA-mRNA interactions using bioinformatics tools, identifying experimentally validated target genes and enriched biological pathways.
Generate evidence for the potential application of miRNAs as diagnostic and prognostic biomarkers in TB-T2DM comorbidity.
TB-T2DM comorbidity represents a growing challenge for health systems, particularly in low- and middle-income countries (LMICs) such as Mexico, India, and China, where the prevalence of T2DM is increasing and TB remains endemic. The identification of shared molecular biomarkers will enable progress toward personalized medicine, capable of stratifying patients according to their risk of developing active TB, optimizing therapeutic regimens, and reducing complications. This approach contributes to understanding the immunometabolic mechanisms underlying the interaction between chronic infections and metabolic diseases, providing evidence for the design of new prevention and treatment strategies.
Methodology
Search strategy
A systematic search was carried out in the PubMed and Google Scholar databases, using Medical Subject Headings (MeSH) terms and keywords related to “microRNA”, “dysregulated expression”, “biomarkers”, “type 2 diabetes mellitus” and “tuberculosis”. The search included articles published from October 2011 to July 2025 in English. Potentially relevant publications were identified through a manual review of titles and abstracts.
Selection criteria
Studies were eligible if they 1) reported miRNA expression profiles in adult human samples related to pulmonary TB or T2DM; 2) specified the biological sample type and study groups; 3) described the methodology used to quantify miRNAs; and 4) clearly reported the differential expression of miRNAs. We excluded systematic reviews and meta-analyses without experimental validation, studies lacking a description of the miRNA detection methodology, and experimental studies conducted in children, animal models, or cell lines.
Quality assessment
The systematic review followed the PRISMA 2020 guidelines, and flow diagrams were used to document the identification, screening, eligibility, and inclusion of studies for each condition (Figures 1, 2). A comprehensive screening of titles, abstracts, and full texts was performed. We did not apply a formal risk of bias assessment tool. A total of 60 articles were evaluated to identify dysregulated miRNAs in pulmonary TB, of which 27 were excluded because they did not meet the selection criteria (Figure 1). In the case of miRNAs selected for DM2, 52 publications were analyzed, and 32 were discarded for the same reason (Figure 2).
Figure 1
Figure 2
Selection of miRNAs with an altered expression profile for both pathologies
In the selection of miRNAs, a review flow was systematically followed, which consisted of 1) review of titles and abstracts, 2) reading of the full text of the articles, and 3) elaboration of a miRNA table for each disease (Tables 1, 2). The names of the miRNAs were standardized using the miRBase database. Subsequently, a comparative table was constructed that included only the dysregulated miRNAs present in both diseases (Table 3).
Table 1
| Author | MicroRNA Name | Pulmonary Tuberculosis | |||
|---|---|---|---|---|---|
| Function / Utility | Methodology | Sample | Country / Population | ||
| Wang C et al., () | hsa-miR-130b hsa-miR-21 hsa-miR-223 hsa-miR-302a hsa-miR-424 hsa-miR-451 hsa-miR-486-5p hsa-miR-144 hsa-miR-133a hsa-miR-365 hsa-miR-424 hsa-miR-500 hsa-miR-661 hsa-miR-892b | Affects the development of immune cells, promoting the pathogenesis of TB | Micro-Array. RT-qPCR (TaqMan). | Peripheral blood (PBMC) | China Adults (35 – 45 years) |
| Latorre I et al., () | hsa-miR-21 hsa-miR-29c hsa-miR-194 hsa-miR-150 | Reduction of host Th1 cell responses. | Micro-Array. RT-qPCR (TaqMan). | Peripheral blood (PBMC) | Spain Adults (> 18 years) |
| Zheng L et al., () | hsa-miR-16 hsa-miR-137 hsa-miR-140-3p hsa-miR-193a-3p hsa-miR-501-5p hsa-miR-598 hsa-miR-95 hsa-miR-101 hsa-miR-150 | Activation of immunoregulatory interactions involved with the TGF-β signaling pathway and the T cell receptor signaling pathway. | Micro-Array. RT-qPCR (TaqMan). | Peripheral blood (PBMC) | Hong Kong Adults (> 18 years) |
| Song Q et al., () | hsa-miR-365 | Regulation the expression of IL-6 by binding to its 3 ́UTR, modulating the immune response against ATB. | RT-qPCR. Western Blot. ELISA. | Bronchoalveolar macrophages, serum and whole blood (PBMC) | China Adults (> 18 years) |
| Liu Y et al., () | hsa-miR-582-5p | Inhibition of monocyte apoptosis in ATB patients by negatively regulating FOXO1 expression. | RT-qPCR. Apoptosis assays by FOXO1 transfection. | Peripheral blood (monocytes) | China Adults (20 - 60 years) |
| Xi X et al., () | hsa-miR-223 | Regulation of the immune response against Mtb by modulation of FOXO3 expression. | RT-qPCR. Apoptosis assays by FOXO3 transfection. | Peripheral blood (PBMC/macrophages) | China Adults (29 - 60 years) |
| Zhang Y et al., () | hsa-miR-892b hsa-miR-199b-5p hsa-miR-582–5p | Regulation of the MAPK signaling pathway and leukocyte migration. | RT-qPCR. | Peripheral blood (PBMC) | China Adults (> 18 years) |
| Alipoor SD et al., () | hsa-miR-484 hsa-miR-425 hsa-miR-96 | Modulation of catabolism and cellular metabolism, inhibition of the innate immune response and promotes the dissemination of Mtb | RT-qPCR. | Serum (exosomes) | Iran Adults (18-65 years) |
| Chakrabarty S et al., () | hsa-miR-146a-5p hsa-miR-486-5p hsa-miR-16-2-3p hsa-miR-144-3p hsa-miR-483-5p hsa-miR-193a-5p hsa-miR-140-3p hsa-miR-125b-5p hsa-miR-425-5p hsa-miR-101-3p hsa-miR-29c-3p hsa-miR-378a-5p hsa-miR-143-3p hsa-miR-378a-3p hsa-miR-378d hsa-miR-378f hsa-miR-378c hsa-miR-29c-5p hsa-miR-22-3p hsa-miR-320a hsa-miR-129-5p hsa-miR-409-3p hsa-miR-370-3p hsa-miR-551b-5p hsa-miR-4523 has-mir-425-5p hsa-miR-4523 | Differentially expressed in TB patients, they modulate pathways involved with cell cycle, transcriptional regulation, apoptosis, mRNA processing, lipid metabolism, and cell-cell communication. | RT-qPCR. | Serum (RNA) | India Adults (30 – 65 years) |
| Massi MN et al., () | has-mir-425-5p hsa-miR-4523 | Differential diagnosis of PTB and LTBI. hsa-mir-425-5p is positively regulated and hsa-mir-4523 is negatively regulated in PTB. | RT-qPCR. | Whole blood (RNA) | Indonesia Adults (25 – 60 years) |
| Adhikary S et al., (27) | hsa-miR-29a | Differential diagnosis of extrapulmonary TB and pulmonary TB. | RT-qPCR. | Serum (RNA) | India Adults (18 - 76 years) |
| Hurtado, J et al., (28) | hsa-miR-126-3p hsa-miR-378a-3p hsa-miR-423-5p | Monitoring of severe cases of TB. | Sequencing (ILLUMINA) RT-q-PCR | Serum (RNA) | Uruguay Adults (> 18 years) |
| El-Masry et al., (29) | hsa-miR-21-5p hsa-miR-29a-3P hsa-miR-361-5p | Diagnostic and prognostic markers of ATB and LTBI in humans. | RT-qPCR. | Whole blood (RNA) | Egypt Adults (> 18 years) |
| Kim, J et al., (30) | hsa-miR199a-3p hsa-miR199b-3p hsa-miR-6856-3p hsa-miR-374c-5p hsa-miR-16-5p | Promising biomarkers for the diagnosis and therapeutic monitoring of ATB. | Sequencing (ILLUMINA) RT-q-PCR | Serum (RNA) | Korea Adults (35 - 43 years) |
| Sun X et al., (31) | hsa-miR-125b | Decreases levels of IL-6, TNF-α, NF-κB and IFN-γ by inhibiting RAF1 | RT-qPCR (TaqMan) | Peripheral blood (PBMC) | China Adults (> 18 years) |
| Ndzi EN et al., (32) | hsa-miR-29a-3p hsa-miR-155-5p hsa-miR-29a-3p | Biomarkers useful for differentiating pulmonary TB from extrapulmonary TB. | RT-qPCR (TaqMan) | Peripheral blood (RNA) | Africa Adults (> 18 years) |
| Barry SE et al., () | hsa-miR-99b hsa-miR-29a hsa-miR-146a hsa-miR-26a hsa-miR -652 | Biomarker profile with potential to predict treatment response. | RT-qPCR (TaqMan) | Plasma (RNA) | China Adults (18 – 69 years) |
| Corral-Fernández et al., (33) | hsa-miR-326 | Modulation of the immune response induced by antituberculosis treatment. | RT-qPCR (TaqMan) | Peripheral blood (PBMC) | Mexico Adults (30 – 55 years) |
| Wang C et al., (34) | hsa-miR-21-5p hsa-miR-92a-3p hsa-miR-148b-3p hsa-miR-125a-5p | Potential biomarkers for monitoring treatment in ATB patients | RT-qPCR (TaqMan) | Plasma (RNA) | China Adults (18 – 65 years) |
| Cui JY et al., (35) | hsa-miR-769-5p hsa-miR-320a hsa-miR-22-3p | Non-invasive biomarkers for the diagnosis and prognosis of ATB | RT-qPCR (TaqMan) | Plasma (RNA) | China Adults (30 – 60 years) |
| Wang C et al., (36) | hsa-miR-365 hsa-miR-29a hsa-miR-16 hsa-miR-155 | Non-invasive biomarkers for early diagnosis and prognostic treatment of ATB | RT-qPCR (TaqMan) | Peripheral blood (PBMC) | China Adults (19 – 77 years) |
| Carranza et al., (37) | hsa-miR-let-7e-5p hsa-miR-197-3p hsa-miR-223-3p | Possible biomarker of therapeutic failure or relapse in DR-TB | Micro-Array. RT-qPCR (TaqMan) | Serum (Exosomes) | Mexico Adults (18 to 77 years) |
| Shepelkova G et al., () | hsa-miR-191 hsa-miR-223 hsa-miR-155 | Biomarker for monitoring treatment and lung destruction | RT-qPCR (TaqMan) | Serum (RNA) | Russia Adults (18 – 65 years) |
| Sun W et al., (38) | hsa-miR-140-5p | Negative regulation of the SNHG16 gene favoring the control of Mtb infection. | RT-qPCR (TaqMan) | Peripheral blood (PBMC) | China Adults (30 – 40 years) |
| Liu G et al., (39) | hsa-miR-125b-5p | Decreased inflammation and increased apoptosis, reducing bacterial load, through negative regulation of DRAM2. | RT-qPCR (TaqMan) | Peripheral blood (PBMC) | China Adults (25 – 65 years) |
| Tu H et al., (40) | hsa-miR-423-5p hsa-miR-17-5p hsa-miR-20b-5p | Inhibition of autophagosome-lysosome fusion by post-transcriptional regulation of VPS33A, favoring Mtb replication. | RT-qPCR (TaqMan) | Serum (RNA) Peripheral blood (PBMC) | China Adults (25 – 55 years) |
| Yang, J. et al., (41) | hsa-miR-15a- 5p | Regulation of key cell cycle genes (CCND1, CDK6, CCND2). Plays a central role in TB pathogenesis. | Sequencing RT-q-PCR | Plasma (RNA) | China Adults (28 – 45 years) |
| Cui, J et al., (42) | hsa-miR-766-3p | Potential diagnostic biomarker and key modulator of the cellular response to Mtb infection by suppressing NRAMP1. | RT-qPCR (TaqMan) | Plasma (Exosomes) | China Adults (20 – 55 years) |
| Liu J et al., (43) | hsa-miR-Let-7d-5p hsa-miR-140-5p | Diagnostic biomarker to differentiate ATB from LTBI. | RT-qPCR (TaqMan) | Serum (RNA) | China Adults (18 – 80 years) |
| Sampath P et al., (44) | hsa-miR-548m hsa-miR-486-3p HSA-MIR-486-3P hsa-miR-132-3p hsa miR-150-5p | Alterations in the expression profile of this panel are associated with immune dysfunction, drug resistance, and severe cases of TB. | Flow cytometry NanoString | Peripheral blood (PBMC) | India Adults (18 - 47 years) |
| Zhang H et al., (45) | hsa-miR-196b hsa-miR-376c | Regulation of the immune response against Mtb. Diagnostic biomarkers of ATB. | RT-qPCR (TaqMan) | Serum (RNA) | China Adults (18 – 45 years) |
| Fu, Y et al., () | hsa-miR-29a hsa-miR-93 hsa-miR-3125 | Potential diagnostic biomarker panel in ATB. | Micro-Array. RT-qPCR (TaqMan) | Serum (RNA) Sputum (RNA) | China Adults (18 – 45 years) |
| Spinelli, S. et al., (46) | has-miR-424 has-miR-146a has-miR-223 has-miR-144 has-miR-421 | Modulation of inflammatory response. Monitoring of anti-Mtb therapy. | RT-qPCR (TaqMan) | Peripheral blood (PBMC) | Argentina Adults (18 – 71 years) |
Selection of dysregulated miRNAs in pulmonary TB, according to the literature consulted.
Table 2
| Author | MicroRNA Name | Type 2 Diabetes Mellitus | |||
|---|---|---|---|---|---|
| Function / Utility | Methodology | Sample | Country / Population | ||
| Karolina DS et al., () | hsa-miR-144 | Affects insulin signaling by decreasing IRS1 expression | RT-qPCR (TaqMan) | Peripheral blood (PBMC) | Singapore Adults (21 – 71 years) |
| Kameswaran V et al., (47) | hsa-miR-7-3-5p | Regulation of insulin secretion and proliferation of pancreatic beta cells. | RNA-Seq RT-q-PCR | Pancreatic beta cell islets (autopsy) | USED Adults (45 – 61 years) |
| Fuentevilla-Alvarez G et al., (48) | hsa-miR-17-5p | Regulation of proliferation, migration, and angiogenesis in endothelial cells. | RT-qPCR (TaqMan) | Peripheral blood (PBMC) | Mexico Adults (> 40 years) |
| Sulaiman F et al., () | hsa-miR-130b-5p hsa-miR-130b-3p hsa-miR-125a-3p hsa-miR-223-5p hsa-miR-143-3p hsa-miR-29a-3p | Related to lipid metabolism and elevated cholesterol levels. Pancreatic beta cell dysfunction. Insulin resistance. Impaired insulin secretion. | RNA-Seq | Peripheral blood (PBMC) | Dubai Adults (18 – 87 years) |
| Ofori et al., () | hsa-miR-130b-3p hsa-miR-130a-3p hsa-miR-152-3p | Failure of insulin production in pancreatic beta cells. | RT-qPCR (TaqMan) | Pancreatic beta cell islets (autopsy) | Sweden Adults (> 18 years) |
| Katayama M et al., (49) | hsa-miR-20b-5p | Increased glycogen synthesis in skeletal muscle cells by the regulation of AKTIP and STAT3 | RT-qPCR (TaqMan) | Peripheral blood (PBMC) | Sweden Adults (> 18 years) |
| Shaker OG et al., (50) | hsa-miR-20b hsa-miR-17-3p | Negative correlation with fasting blood glucose, triglycerides, and glycosylated hemoglobin. | RT-qPCR (TaqMan) | Peripheral blood (PBMC) | Egypt Adults (49 – 55 years) |
| Weale CJ et al., (51) | hsa-miR-1299 hsa-miR-126-3p hsa-miR-30e-3p | Associated with prediabetes, diabetes, and micro- and macrovascular complications. Negative correlation with abdominal circumference. Positive correlation with glucose and HDL cholesterol levels. | RT-qPCR (TaqMan) | Peripheral blood (RNA) | South Africa Adults (> 45 years) |
| Roux M et al., (52) | hsa-miR-152-3p | Associated with diabetic nephropathy and loss of plasma osmolarity due to silencing of the SLC5A3 gene. | RT-qPCR (TaqMan) | Peripheral blood (RNA) | France Adults (> 18 years) |
| Ali H et al., (53) | hsa-miR-151a-3p hsa-miR-182-5p | Related to cell growth and differentiation, glucose and lipid metabolism in patients with DM2 and diabetic nephropathy. Modulation of gene expression (PTEN, SMAD2, SMAD4, VEGF, CCND2, CDK6, LIN28B, and CHD1). | RNA-Seq | Urine (extracellular vesicles) | Asia Adults (> 18 years) |
| Greco M et al., (54) | hsa-miR-1281 | Increased VEGFA expression. Related to diabetic retinopathy. | RT-qPCR (TaqMan) | Peripheral blood (RNA) | Italy Adults (18 -60 years) |
| Syed TR et al., (55) | hsa-miR-126 hsa-miR-486 hsa-miR-223 hsa-miR-375 | Inhibition of the insulin receptors IRS1 and GLUT4. Promotes insulin resistance. Associated with elevated levels of fasting blood glucose and glycosylated hemoglobin. | RT-qPCR (TaqMan) | Peripheral blood (RNA) | India Adults (< 45 years) |
| Yang T. T. et al., (56) | hsa-miR-155 | Involved in the pathogenesis of T2DM retinopathy by regulating Treg cells with TGF-β. | RT-qPCR (TaqMan) | Peripheral blood (RNA) | China Adults (37 – 78 years) |
| Xu Bai et al., (57) | hsa-miR-155 | Potential biomarker of retinopathy and nephropathy in patients with T2DM | RT-qPCR (TaqMan) | Peripheral blood and urine (RNA). | China Adults (63 – 73 years) |
| Guglielmi V et al., (58) | hsa-miR-21 | Related to insulin resistance and progression of obesity | RT-qPCR (TaqMan) | Subcutaneous adipocytes (RNA) | Italy Adults (> 40 years) |
| McClelland A. et al., (59) | hsa-miR-21 | Related to the development of kidney disease and fibrosis in patients with T2DM. | RT-qPCR (TaqMan) | Renal biopsy (RNA) | Israel Adults |
| Meng X et al., (60) | hsa- miR23a-3p | Association with severe kidney disease in patients with T2DM | RT-qPCR (TaqMan) | Serum (RNA). | China Adults (> 30 years) |
| Lozano-Bartolomé J et al., (61) | hsa-miR23a-3p hsa-miR181a-5p | Negative correlation with insulin resistance | RT-qPCR (TaqMan) | Adipose tissue (RNA) Serum (RNA) | Spain Adults (45 – 55 years |
| Fang Y et al., (62) | hsa-miR183a-5p hsa-miR125a-5p | Association with insulin signaling and glucose transport. | RT-qPCR (TaqMan) | Urine | China Adults (> 30 years) |
| Zhang T et al., () | hsa-miR-126 | Decreased miR-126 may be an early marker of T2DM. | RT-qPCR (TaqMan) | Plasma (RNA). | China Adults (> 30 years) |
Selection of dysregulated miRNAs in DM2, according to the literature consulted.
Table 3
| microRNA name | Expression | |
|---|---|---|
| Pulmonary tuberculosis | Type 2 diabetes mellitus | |
| hsa-miR-21 | Up | Up |
| hsa-miR-125a-5p | Up | Up |
| hsa-miR-486 | Up | Down |
| hsa-miR-223 | Up | Up |
| Down | Down | |
| hsa-miR-144 | Up | Up |
| hsa-miR-130b-5p | Down | Down |
| hsa-miR-125a-3p | Up | Up |
| hsa-miR-223-5p | Up | Up |
| hsa-miR-29a-3p | Up | Up |
| hsa-miR-130b-3p | Down | Up |
| hsa-miR-130a-3p | Up | Up |
| hsa-miR-155 | Up | Up |
dysregulated miRNAs in both conditions (pulmonary TB and DM2).
Bioinformatics analysis
Once the dysregulated miRNAs in DM2 and TB were identified, the list of target mRNAs was obtained. To do this, the miRNet v2.0 (https://www.mirnet.ca/miRNet/home.xhtml) database was consulted, loading the list of overexpressed, underexpressed, and variable expression miRNAs in both diseases. Subsequently, from each list of miRNAs, the mRNAs that have been experimentally validated and reported in the miRTarBase v9.0 (https://mirtarbase.cuhk.edu.cn/~miRTarBase/miRTarBase_2025/php/index.php) database were obtained. The significant interactions between miRNAs-mRNAs obtained to build the network using Cytoscape v3.10.3 were obtained. The CytoHubba v0.1 application was used to obtain the most central genes of the miRNA-mRNA network, based on the value of the percolated component of bonds (EPC).
To identify the functional annotation of the miRNAs and target genes, a pathway analysis was performed using the R v4.5.0 programming language with the ClusterProfiler v4.16.0 (63) and the DIANA-miRPath v3.0 platform (https://dianalab.e-ce.uth.gr/html/mirpathv3/index.php?r=mirpath) (64). For the R-based analysis, the list of target mRNAs obtained from miRNet was used, and gene sets from the Molecular Signatures Database (MSigDB) were downloaded with the msigdbr v25.1.0 package, retaining only those pathways relevant to the immune response against tuberculosis. For the DIANA-miRPath v3.0 analysis, the names of the shared miRNAs were uploaded, and pathway enrichment was evaluated using Gene Ontology (GO) biological process terms.
Results
Identification of dysregulated miRNAs shared between tuberculosis and type 2 diabetes mellitus
The systematic review revealed miRNAs with comparable expression changes in TB and T2DM patients. They were grouped into three categories: overexpressed, underexpressed, and variably expressed, highlighting the heterogeneity reported across studies.
Identifying these shared miRNAs suggests convergent molecular mechanisms that may partly explain the heightened TB susceptibility in diabetic patients (65–67).
Analysis of miRNAs-mRNA interaction networks and identification of target genes
To understand the functional implications of the shared miRNAs, we queried the miRNet v2.0 database with the list of dysregulated miRNAs to retrieve their target mRNAs. The analysis uncovered a network of interactions, including 2,887 targets for overexpressed miRNAs, 355 for underexpressed, and 853 for variably expressed. (Figures 3A, 4A, 5A). This network indicates that shared miRNAs influence diverse intracellular pathways, modulating immune, metabolic, and signaling processes essential for host defense against Mtb (, 68, 69). The differential in the number of target genes identified for each category of miRNAs reflects the regulatory complexity inherent in these non-coding RNAs. Overexpressed miRNAs more effectively repress target mRNAs, accounting for the larger number of targets and their wider impact on cell physiology (70–72).
Figure 3
Figure 4
Figure 5
For underexpressed miRNAs, other mechanisms, such as long non-coding RNAs (lncRNAs), may influence their levels. For example, lncRNAs act as sponges for miRNAs, decreasing their expression (73).
Functional enrichment analysis: biological processes regulated by shared MiRNAs
Overexpressed miRNAs: suppression of essential immune processes
The biological pathway enrichment analysis performed on the DIANA-miRPath platform revealed that overexpressed miRNAs in both pathologies regulate pathways involved in extracellular matrix remodeling and organization.
Specifically, hsa-miR-29a-3p is implicated in collagen catabolism and cell adhesion in the extracellular matrix (Figure 3B). In vitro studies carried out on endothelial cells from different tissues have shown that the overexpression of hsa-miR-29a-3p decreases the expression of adhesion molecules such as VCAM-1, ICAM-1, and E-Selectin (74). These results suggest that miRNAs regulate genes associated with extracellular matrix organization, thereby influencing cell adhesion. On the other hand, pathway analysis focused on the target mRNAs of overexpressed miRNAs revealed that there is a downregulation of the expression of genes involved in immunological processes critical for the defense against tuberculosis, including leukocyte adhesion, differentiation, and migration, as well as the tuberculosis-specific immune response (Figure 3C). This finding is pathophysiologically relevant, as the overexpression of these shared miRNAs may suppress host defense mechanisms, facilitating latent TB reactivation in diabetic patients and progression of active disease (65–67). Leukocyte adhesion and migration are essential for immune cell recruitment to infection sites and for granuloma development and stability (75–77).
The alteration of these processes in the context of TB-T2DM comorbidity has been documented in transcriptomic studies, where alterations in cell trafficking and granuloma architecture are observed, potentially contributing to increased bacillary load and reduced immune efficacy in diabetic patients (66, 67, 78, 79).
Leukocyte differentiation, particularly macrophage polarization toward M1 or M2 phenotypes, influences the balance between bacterial control and tissue immunopathology (65, 79, 80).
Hyperglycemia in DM2 alters macrophage polarization, promoting phenotypes less effective in Mtb clearance and antigen presentation (65, 78). The overexpression of miRNAs targeting genes involved in leukocyte differentiation may sustain immune dysfunction, impairing mycobacterial clearance (81, 82).
Underexpressed and variably expressed miRNAs: regulation of cell metabolism
In contrast to overexpressed miRNAs, pathway analysis of underexpressed or variably expressed miRNAs in the context of the immune response to tuberculosis did not yield statistically significant results.
Nevertheless, functional enrichment analysis using the Gene Ontology Biological Process database indicated that mRNAs regulated by these miRNAs participate in key metabolic processes, including nitrogenous base metabolism, glucose metabolism, miRNA biogenesis, and the development of specialized tissues such as endocrine glands and vascular endothelium (Figures 4B, 5B).
These findings suggest that underexpressed and variably expressed miRNAs may contribute to the pathophysiology of TB–T2DM comorbidity by modulating metabolic pathways that, while not directly linked to the innate immune response against tuberculosis, are essential for maintaining cellular and tissue homeostasis under metabolic and infectious stress (66, 79). For instance, glucose metabolism is critical for both immune cell activity and glycemic control in T2DM, and its dysregulation can worsen both conditions (66, 83). Moreover, TB has been reported to impair the function of glands such as lymph nodes, adrenal glands, and the thyroid (84, 85), leading to endocrine disturbances that influence immune activation (86).
Because subsequent analyses aimed to clarify immunological mechanisms directly associated with tuberculosis susceptibility and progression in the context of diabetes, we concentrated on overexpressed miRNAs, whose functional impact on the immune response was more evident and statistically significant.
Identification of core genes (hub genes) in the miRNA-mRNA network
To explore the functional interactions between overexpressed miRNAs and their target mRNAs, a molecular interaction network was constructed using experimentally validated targets from the miRTarBase v9.0 database. Work centrality analysis, with the CytoHubba application, identified 11 mRNAs with high centrality (hub genes), representing key nodes in the regulatory network: DICER1, SP1, STAT3, MYC, CDK4, PTEN, BCL2, SMAD4, NAA50, EGFR, and CFL2 (Figure 6A).
Figure 6
These hub genes have pleiotropic roles in regulating fundamental cellular processes. DICER1, a ribonuclease essential for miRNA biogenesis, functions as a central regulator of the RNA interference system, and modulation by miRNAs may establish feedback loops that amplify or attenuate regulatory signals (71, 72).
SP1 is a ubiquitous transcription factor that regulates genes involved in cell proliferation, apoptosis, and immune response (87). STAT3 is an important transcription factor in cytokine signaling and in regulating both innate and adaptive immune responses (87–89). In the context of tuberculosis, STAT3 has been implicated in macrophage activation and in the response to interferon-gamma (IFN-γ), a cytokine essential for controlling Mtb (87).
Previous studies have shown that polymorphisms in the STAT3 gene have been associated with susceptibility in human populations, and their dysfunction compromises innate immunity against mycobacteria (87). In patients with TB-T2DM comorbidity, hyperglycemia induces aberrant STAT3 phosphorylation, contributing to immune dysfunction (89).
Experimental studies indicate that phosphorylated STAT3 suppresses specific miRNAs (such as miR-19b and miR-1281), worsening lung damage in mouse models of DM2-associated TB (89).
MYC is a proto-oncogene that regulates genes involved in cell cycle, metabolism, and apoptosis. In tuberculosis, MYC expression has been linked to dysregulation of macrophage antimicrobial activity in controlling Mtb infection (90).
BCL2 is an anti-apoptotic regulator that protects cells from apoptosis, and its dysregulation can affect infected cell survival and immune responses (66, 78).
PTEN is a tumor suppressor that antagonizes the PI3K/AKT pathway, modulating insulin signaling and glucose metabolism, processes central of T2DM pathogenesis.
The identification of EGFR (Epidermal Growth Factor Receptor) as a hub gene suggests a connection between growth factor signaling and response to infection and metabolism. CDK4 (Cyclin-Dependent Kinase 4) regulates cell cycle progression, while SMAD4 mediates signaling by TGF-β, a cytokine with complex roles in immunity and fibrosis. NAA50 and CFL2 are less characterized in the context of TB-T2DM, but their identification as central nodes warrants further investigation.
Target gene protein-protein interaction network
To further characterize the functional interactions of the target genes of overexpressed miRNAs, a protein-protein interaction (PPI) was constructed using the STRING database. The centrality analysis of this PPI network identified 10 genes with high centrality: STAT3, MYC, BCL2, AKT1, CTNNB1, JUN, IL-6, TP53, TNF, and HIF1A (Figure 6B).
These hub genes represent regulators involved in both tuberculosis immunity and the pathophysiology of type 2 diabetes mellitus. AKT1 is a central component of the PI3K/AKT signaling pathway, essential for insulin signaling, glucose and lipid metabolism, and cell survival.
The AKT pathway regulates GLUT4 and GLUT1-mediated glucose transport, glycogen synthesis, hepatic gluconeogenesis, and lipogenesis, processes altered in T2DM.
In addition, AKT1 also regulates pancreatic β cell function, regulating insulin secretion and the adaptive stress response of the endoplasmic reticulum.
In the context of tuberculosis, AKT signaling in macrophages modulates phagocytosis, production of reactive oxygen and nitrogen species, and response to proinflammatory cytokines (66, 78).
HIF1A is a transcription factor that regulates the cellular response to hypoxia, a condition characteristic of the granuloma microenvironment in the tuberculous (75–77, 91, 92). HIF-1α coordinates metabolic adaptation toward aerobic glycolysis, increases glucose transporter expression (GLUT1), and regulates proinflammatory cytokine production (93–96).
In macrophages infected with Mtb, HIF-1α is essential for IFN-γ-induced activation and for the control of intracellular bacterial replication (93, 94). Stabilization of HIF-1α under conditions of granulomatous hypoxia promotes antimicrobial mechanisms, including autophagy and antimicrobial peptide production (83, 93, 94). However, in the context of T2DM, hyperglycemia and carbonyl stress (e.g., methylglyoxal, MGO) impair HIF-1α-regulated responses, compromising the control of Mtb in macrophages (83).
Experimental studies indicate that desferrioxamine (DFO), a stabilizer of HIF-1α, restores mycobacterial control under high-glucose conditions, suggesting HIF-1α as a potential therapeutic target to enhance the immune response in patients with T2DM-TB (83). In addition, HIF-1α regulates the expression of matrix metalloproteinases (MMPs) in hypoxic macrophages infected with Mtb, contributing to tissue damage and the formation of lung cavities characteristic of advanced tuberculosis (97).
TNF and IL-6 are key proinflammatory cytokines in tuberculosis immunity and T2DM pathogenesis (66, 76, 78–80, 92). TNF is essential for the formation and maintenance of granulomas, the recruitment of immune cells, and the activation of macrophages (76, 92).
However, excessive or dysregulated TNF production contributes to immunopathology, tissue necrosis, and cachexia (76, 92). In diabetic TB patients, TNF levels are frequently elevated, contributing to a state of chronic inflammation that exacerbates both insulin resistance and lung tissue damage (66, 78). IL-6 regulates the acute-phase response, B and T cell activation, and Th17 cell differentiation, and elevated IL-6 levels are associated with insulin resistance and diabetic complications (66, 92).
TP53 is a tumor suppressor that regulates the cellular stress response, apoptosis, and senescence. JUN is a component of the transcription factor AP-1, involved in proliferation, differentiation, and stress response. CTNNB1 (β-catenin) is a mediator of Wnt signaling, with roles in development, tissue homeostasis, and metabolism.
The convergence of these hub genes into a densely interconnected network suggests that the overexpressed miRNAs shared between TB and T2DM function as pleiotropic regulators, simultaneously modulating key cellular processes, such as insulin signaling (AKT1, PTEN), hypoxia response (HIF1A), inflammation (TNF, IL-6), apoptosis (BCL2, TP53), and metabolic adaptation. Convergence of these hub genes into a densely interconnected network suggests that overexpressed miRNAs shared between TB and T2DM function as pleiotropic regulators, simultaneously modulating key cellular processes such as insulin signaling (AKT1, PTEN), hypoxia response (HIF1A), inflammation (TNF, IL6), apoptosis (BCL2, TP53), and metabolic adaptation. Network architecture offers a framework for understanding how miRNA dysregulation may contribute to TB–T2DM comorbidity, connecting metabolic dysfunction with impaired immune responses.
Integrated biological interpretation
Taken together, the bioinformatic results suggest that the overexpressed miRNAs shared between TB and T2DM repress genes essential for the innate and adaptive immune response against Mtb. Suppression of processes such as leukocyte adhesion, migration, and differentiation reduces the host’s capacity to recruit effector cells from granulomas and eliminate intracellular bacteria (65–67, 78, 79) (Table 4). At the same time, modulation of central metabolic pathways (glucose metabolism, insulin signaling, response to hypoxia) sustains a state of metabolic-immunological dysfunction that promotes both T2DM progression and TB reactivation and dissemination (66, 79, 80, 83).
Table 4
| Biological Process | P adjusted | Genes Hub |
|---|---|---|
| Myeloid leukocyte differentiation | 4.61E-07 | MYC, TNF, CTNNB1, JUN |
| Response to molecule of bacterial origin | 1.69E-05 | CDK4, TNF, AKT1, IL6 |
| Positive regulation of leukocyte migration | 0.00029956 | TNF, IL6 |
| Leukocyte apoptotic process | 0.00052312 | BCL2, MYC, HIF1A, AKT1, TP53, IL6 |
| Regulation of leukocyte differentiation | 0.00073687 | MYC, TNF, CTNNB1 |
| Positive regulation of leukocyte chemotaxis | 0.00095156 | IL6 |
| T cell differentiation involved in immune response | 0.00095156 | STAT3, IL6 |
| Regulation of myeloid leukocyte differentiation | 0.00095156 | MYC, TNF, CTNNB1 |
| Leukocyte cell adhesion | 0.00095156 | TNF, AKT1, IL6 |
Top immunological processes and the hub genes related to tuberculosis.
In addition, inhibition of apoptosis-related genes contributes to infection spread and poorer prognosis in patients with active TB (98).
Finally, these findings highlight the importance of systems biology approaches to understand complex diseases with multiple comorbidities, where the interaction among miRNA, mRNA, proteins, and metabolic pathways generates emergent properties not predictable from the study of individual components (, 65–69).
Figure 7 synthesizes the convergent molecular mechanisms identified in this study, showing dysregulated miRNAs shared between TB and T2DM along with their experimentally validated target genes and associated biological processes.
Figure 7
Discussion
The present systematic review identified a set of miRNAs whose expression is jointly dysregulated in patients with pulmonary TB and T2DM and characterized the molecular networks through which these miRNAs modulate immunological and metabolic processes critical for the pathophysiology of both diseases. To our knowledge, the present study is the first to carry out a systematic review, analyzing the miRNAs that are involved in the TB-T2DM comorbidity. Currently, the shared biological mechanisms underlying both diseases are not fully elucidated. Therefore, there is a need to find prognostic, diagnostic, or follow-up biomarkers or molecules that can represent potential molecular targets.
The main findings of this study reveal that shared overexpressed miRNAs negatively regulate genes involved in leukocyte adhesion, migration, differentiation, and cell death, as well as in the specific immune response against TB. The network analysis identified high-centrality hub genes, including STAT3, AKT1, HIF1A, TNF, IL-6, BCL2, MYC, and PTEN, that constitute critical nodes of integration between metabolism and immunity. These genes represent potential therapeutic targets for host-directed therapies in patients with TB-DM2 comorbidity (65, 66, 75, 83, 87, 89, 93). For example, restoring HIF-1α function using pharmacological stabilizers, modulating AKT signaling to improve both insulin sensitivity and macrophage function, and balanced regulation of proinflammatory cytokines such as TNF and IL-6 are promising strategies that deserve exploration in future preclinical and clinical studies (66, 80, 83). Our results provide a robust conceptual framework for understanding the molecular mechanisms that link the metabolic dysfunction characteristic of T2DM with immunosuppression that favors TB reactivation and progression and suggest multiple translational applications of clinical and public health relevance.
Circulating miRNAs have emerged in the last decade as promising molecular biomarkers for the diagnosis of infectious and metabolic diseases due to their unique biological properties: high stability in body fluids (serum, plasma, urine, sputum), resistance to degradation by RNases, tissue- and disease-specific expression profiles, and accessibility through non-invasive detection techniques (99–103). In the context of TB, multiple studies have shown that specific miRNAs such as miR-29a, miR-155, miR-425-5p, let-7d-5p, and miR-140-5p can discriminate between tuberculosis infection, active TB, and healthy controls with sensitivities ranging from 78% to 94% and specificities ranging from 76% to 92% (, 43, 101, 104–107). Similarly, in T2DM, circulating miRNAs such as miR-126, miR-122, miR-146a, miR-192, and miR-194 have shown diagnostic and prognostic utility, predicting progression from prediabetes to established diabetes and stratifying the risk of microvascular and macrovascular complications (108–114). Our study highlights hsa-miR-155-5p and hsa-miR-29a-3p, which are overexpressed in TB and T2DM and appear to be central regulators of extracellular matrix adhesion and remodeling. Previous reports indicate that hsa-miR-29a-3p is linked to inhibition of cell adhesion and migration. Specifically, this miRNA decreases the expression of genes such as VCAM-1, ICAM-1, and E-cadherin in endothelial cells, which affects the adhesion of leukocytes (74). With respect to hsa-miR-155-5p, it has been reported that the overexpression of this miRNA in bone marrow-derived neutrophils favors NETosis, increasing the damage caused by inflammation exacerbated by this type of cell death (115). NETosis, and its molecular markers, is associated with granuloma destruction and caseous center formation in patients with active TB (116). The findings reported in the present study suggest that hsa-miR-155-5p and hsa-miR-29a-3p could be potential molecular targets in the TB-T2DM comorbidity, as they regulate key cellular processes that are involved in TB immunopathology. However, further studies are required to better understand the involvement of these miRNAs in TB and T2DM.
The identification of deregulated miRNAs shared between TB and T2DM in the present study opens innovative perspectives for the development of integrated diagnostic biomarkers specific to TB-T2DM comorbidity. These biomarkers could facilitate bidirectional screening, identifying TB patients who are at high risk of developing undiagnosed T2DM or prediabetes and detecting diabetic patients at high risk of ITL reactivation or progression to active TB (117–121). This early detection strategy is particularly relevant in contexts with a high burden of both diseases, where diagnostic resources are limited and underdiagnosis rates are high (119–121).
From a technical perspective, the development of diagnostic panels based on multiple miRNAs has demonstrated superior performance to single miRNAs in studies of TB and other diseases (43, 122, 123). Similarly, a panel combining let-7d-5p and miR-140-5p distinguished ITL from active TB with AUC of 0.93 and 100% sensitivity (43). These results demonstrate that the rational design of multimiRNA panels, integrating differential expression information, network analysis, and functional validation, can significantly optimize diagnostic performance (43, 101, 107).
In the context of TB-T2DM comorbidity, we propose that the shared miRNAs identified in this study, particularly those that regulate hub genes such as STAT3, AKT1, HIF1A, TNF, and IL-6, could constitute priority candidates for the development of molecular signatures of high diagnostic and prognostic value. The measurement of these miRNAs in serum or plasma samples using ultra-sensitive techniques such as Single Molecule Arrays (Simoa) or real-time quantitative PCR (RT-QPCR) would allow patients to be stratified according to risk profiles, to identify subgroups that would benefit from preventive interventions (LTI treatment in diabetics, intensive glycemic control in TB patients), and to monitor the response to antituberculosis and antidiabetic treatment in an integrated manner (101, 105, 107, 124).
A critical aspect for the clinical translation of these biomarkers is methodological standardization and validation in prospective multicenter cohorts. Previous studies have identified important challenges related to the normalization of circulating miRNA levels, the selection of appropriate endogenous controls (such as miR-93 in TB), inter-assay variability, and the need to consider demographic and clinical confounders (age, sex, body mass index, concomitant drug treatments) that may affect miRNA profiles (102, 125–127). Overcoming these technical challenges through standardized protocols and rigorous quality controls is essential to ensure the reproducibility and reliability of miRNA-based biomarkers (100, 102, 125).
In addition, the integration of miRNA profiling with other molecular biomarkers such as inflammatory cytokines (IFN-γ, TNF, IL-6), acute phase markers (C-reactive protein, ferritin), and biomarkers of metabolic function (glycosylated hemoglobin HbA1c, C-peptide, insulin resistance indices) could generate high-throughput, multiparametric diagnostic algorithms that capture the multidimensional complexity of TB-T2DM comorbidity (, 66, 120). Such algorithms, implemented in point-of-care molecular diagnostic platforms, would have a transformative impact in resource-limited contexts, where access to specialized laboratories is restricted and the need for fast, accurate, and inexpensive diagnostics is critical (102, 120, 128).
Figure 8 visually summarizes the main findings of this systematic review and bioinformatics analysis, integrating into a single diagram the epidemiological, molecular, and translational elements that link TB and T2DM. The top portion highlights the epidemiological convergence between the two diseases, underscoring the high prevalence in low- and middle-income countries and the increased risk of TB in patients with T2DM. The center illustrates the shared microRNAs (miR-21, miR-29a, miR-144, miR-155, miR-223, among others), along with the immunometabolic signaling pathways they regulate (NF-κB, TLR, JAK/STAT, mTOR), and the hub genes identified through network analysis (STAT3, AKT1, HIF1A, TNF, IL-6, TP53), reflecting the common molecular architecture between the two pathologies. At the extremes, the altered immunological and metabolic processes are shown, such as cell adhesion, migration, insulin signaling, and the response to hypoxia, which explain the adverse clinical outcomes observed in TB-T2DM comorbidity. Finally, at the bottom, the translational applications of these findings are summarized: from the development of biomarkers for early diagnosis and therapeutic monitoring to the design of host-directed therapies and public health strategies aimed at reducing the global burden of TB. This figure allows for an integrated visualization of how shared miRNAs act as central nodes in the immunometabolic interaction between TB and T2DM, offering new opportunities for personalized medicine and preventive intervention.
Figure 8
The absence of a weighting system constitutes a methodological limitation of this work. Our approach was aimed at identifying recurrent nodes of interaction between miRNAs and target genes, with the purpose of building a conceptual map of the shared mechanisms in TB-DM2 comorbidity. However, we recognize that incorporating quantitative metrics such as effect size and sample size would strengthen the validity of the conclusions and provide a more robust synthesis. In this sense, future studies should integrate these metrics into their analyses to more accurately assess the biological and clinical relevance of the identified miRNAs.
This paper has some limitations that should be considered when interpreting the findings. First, the methodological heterogeneity of the included studies in terms of sample size, population characteristics, and miRNA detection techniques may introduce bias and limit the direct comparability of the results. Second, although the PRISMA 2020 guidelines were followed, a standardized risk of bias assessment tool was not applied, which restricts critical assessment of the quality of the primary evidence. Likewise, the analysis was limited to studies conducted in adult humans. Finally, the results are based on bioinformatic analyses without their own clinical validation, so the proposed diagnostic or therapeutic applications should be considered preliminary and require confirmation in prospective and functional studies.
Conclusion
In the present study, altered miRNAs in TB and T2DM were analyzed through a bioinformatic analysis of a systematic review of the literature published to date. The miRNAs that are shared and overexpressed in both pathologies establish a complex network with their respective target genes, which regulates biological and immunological processes that are important in the response to infection with the mycobacterium. The findings of this research provide new knowledge in the understanding of the complex relationship between the two diseases, clarifying the molecular mechanisms involved in the immunopathology of this binomial.
The translation of our findings into clinical applications could have a significant impact on the reduction of morbidity and mortality associated with this comorbidity, since the identified miRNAs, as well as their molecular targets, could be used as molecular targets and as diagnostic or predictive biomarkers. These findings will be of great interest to contribute to the sustainability of health systems and the achievement of the health-related sustainable development goals.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
Author contributions
CC: Conceptualization, Supervision, Writing – review & editing, Project administration. RC-D: Formal analysis, Methodology, Writing – review & editing. MV: Writing – original draft. MT: Writing – review & editing. IC-G: Writing – original draft. EH-D: Writing – original draft. MC-A: Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This review was funded by the Instituto Nacional de Enfermedades Respiratorias (INER) “Ismael Cosío Villegas (B03-20) and Secretary of Science, Humanities, Technology and Innovation (CBF 2023-2024-4078). Had no role in the study design, collection, analysis, and interpretation of data, the report’s writing, or the decision to submit the article for publication.
Acknowledgments
We are very grateful to Francisco E. Camacho-Mezquita for your support in English editing.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Global Tuberculosis Report 2024. 1st ed. Geneva: World Health Organization (2024). p. 1.
2
MaglianoDBoykoEJ. IDF diabetes atlas. 10th edition. Brussels: International Diabetes Federation (2021). p. 1.
3
BakerMAHarriesADJeonCYHartJEKapurALönnrothKet al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med. (2011) 9:81. doi: 10.1186/1741-7015-9-81
4
JeonCYMurrayMB. Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies. PloS Med. (2008) 5:e152.
5
RestrepoBI. Diabetes and tuberculosis. Microbiol Spectr. (2016) 4:1091–101. doi: 10.1128/microbiolspec.TNMI7-0023-2016
6
BartelDP. MicroRNAs: target recognition and regulatory functions. Cell. (2009) 136:215–33. doi: 10.1016/j.cell.2009.01.002
7
GuayCRegazziR. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol. (2013) 9:513–21. doi: 10.1038/nrendo.2013.86
8
SinghYKaulVMehraAChatterjeeSTousifSDwivediVPet al. Mycobacterium tuberculosis controls microRNA-99b (miR-99b) expression in infected murine dendritic cells to modulate host immunity. J Biol Chem. (2013) 288:5056–61. doi: 10.1074/jbc.C112.439778
9
FuYYiZWuXLiJXuF. Circulating microRNAs in patients with active pulmonary tuberculosis. J Clin Microbiol. (2011) 49:4246–51. doi: 10.1128/JCM.05459-11
10
BarrySEEllisMYangYGuanGWangXBrittonWJet al. Identification of a plasma microRNA profile in untreated pulmonary tuberculosis patients that is modulated by anti-mycobacterial therapy. J Infection. (2018) 77:341–8. doi: 10.1016/j.jinf.2018.03.006
11
XiXZhangCHanWZhaoHZhangHJiaoJ. MicroRNA-223 is upregulated in active tuberculosis patients and inhibits apoptosis of macrophages by targeting FOXO3. Genet Testing Mol Biomarkers. (2015) 19:650–6. doi: 10.1089/gtmb.2015.0090
12
ShepelkovaGSEvstifeevVVTarasovRVErgeshovaAEBagirovMAYeremeevVV. MicroRNAs as biomarkers of active pulmonary TB course. Microorganisms. (2023) 11:626. doi: 10.3390/microorganisms11030626
13
KarolinaDSArmugamATavintharanSWongMTKLimSCSumCFet al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. Navarro A editor. PloS One. (2011) 6:e22839.
14
ZhangTLiLShangQLvCWangCSuB. Circulating miR-126 is a potential biomarker to predict the onset of type 2 diabetes mellitus in susceptible individuals. Biochem Biophys Res Commun. (2015) 463:60–3. doi: 10.1016/j.bbrc.2015.05.017
15
OforiJKSalunkheVABaggeAVishnuNNagaoMMulderHet al. Elevated miR-130a/miR130b/miR-152 expression reduces intracellular ATP levels in the pancreatic beta cell. Sci Rep. (2017) 7:44986. doi: 10.1038/srep44986
16
SulaimanFKhyriemCDsouzaSAbdulFAlkhnbashiOFarajiHet al. Characterizing circulating microRNA signatures of type 2 diabetes subtypes. IJMS. (2025) 26:637. doi: 10.3390/ijms26020637
17
EckoldCKumarVWeinerJAlisjahbanaBRizaALRonacherKet al. Impact of intermediate hyperglycemia and diabetes on immune dysfunction in tuberculosis. Clin Infect Diseases. (2021) 72:69–78. doi: 10.1093/cid/ciaa751
18
WangCYangSSunGTangXLuSNeyrollesOet al. Comparative miRNA expression profiles in individuals with latent and active tuberculosis. PloS One. (2011) 6:e25832. doi: 10.1371/journal.pone.0025832
19
LatorreILeidingerPBackesCDomínguezJDe Souza-GalvãoMLMaldonadoJet al. A novel whole-blood miRNA signature for a rapid diagnosis of pulmonary tuberculosis. Eur Respir J. (2015) 45:1173–6. doi: 10.1183/09031936.00221514
20
ZhengLLeungELeeNLuiGToKFChanRCYet al. Differential microRNA expression in human macrophages with mycobacterium tuberculosis infection of beijing/W and non-beijing/W strain types. PloS One. (2015) 10:e0126018. doi: 10.1371/journal.pone.0126018
21
SongQLiHShaoHLiCLuX. MicroRNA-365 in macrophages regulates Mycobacterium tuberculosis-induced active pulmonary tuberculosis via interleukin-6. Int J Clin Exp Med. (2015) 8:15458–65.
22
LiuYJiangJWangXZhaiFChengX. miR-582-5p is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO1. PloS One. (2013) 8:e78381. doi: 10.1371/journal.pone.0078381
23
ZhangYZhangXZhaoZZhengYXiaoZLiF. Integrated bioinformatics analysis and validation revealed potential immune-regulatory miR-892b, miR-199b-5p and miR-582–5p as diagnostic biomarkers in active tuberculosis. Microbial Pathogenesis. (2019) 134:103563. doi: 10.1016/j.micpath.2019.103563
24
AlipoorSDTabarsiPVarahramMMovassaghiMDizajiMKFolkertsGet al. Serum exosomal miRNAs are associated with active pulmonary tuberculosis. Dis Markers. (2019) 2019:1–9. doi: 10.1155/2019/1907426
25
ChakrabartySKumarARaviprasadKMallyaSSatyamoorthyKChawlaK. Host and MTB genome encoded miRNA markers for diagnosis of tuberculosis. Tuberculosis. (2019) 116:37–43. doi: 10.1016/j.tube.2019.04.002
26
MassiMNHidayahNHandayaniIIskandarIWDjannahFAngriaNet al. microRNA hsa-miR-425-5p and hsa-miR-4523 expressions as biomarkers of active pulmonary tuberculosis, latent tuberculosis infection, and lymph node tuberculosis. Non-coding RNA Res. (2023) 8:527–33. doi: 10.1016/j.ncrna.2023.07.001
27
AdhikarySLeoSBanerjeeAPathakSNarasimhanMRathinamS. Evaluating the expression level of serum Interleukin-2, lipoarabinomannan and circulating MicroRNA-29a as diagnostic biomarkers for pulmonary and extra-pulmonary tuberculosis: a pilot study. Ann Med. (2025) 57:2527949. doi: 10.1080/07853890.2025.2527949
28
HurtadoJBuroniMGiordanoANinNHurtadoFJTosarJPet al. Serum-derived host miR-423-5p and miR-378a-3p as molecular markers for severe tuberculosis: a promising prognostic tool for survival. Front Tuberc. (2024) 2:1441258. doi: 10.3389/ftubr.2024.1441258
29
El-MasryEASamirMTahaAE. Candidate blood microRNAs as potential biomarkers in patients with active and latent pulmonary tuberculosis infection. J Pure Appl Microbiol. (2024) 18:568–83. doi: 10.22207/JPAM.18.1.40
30
KimJParkHParkSBLeeEJJeMAAhnEet al. Identification of microRNAs as potential blood-based biomarkers for diagnosis and therapeutic monitoring of active tuberculosis. Diagnostics. (2022) 12:369. doi: 10.3390/diagnostics12020369
31
SunXLiuKWangXZhangTLiXZhaoY. Diagnostic value of microRNA−125b in peripheral blood mononuclear cells for pulmonary tuberculosis. Mol Med Rep. (2021) 23:249. doi: 10.3892/mmr.2021.11888
32
NdziENNkenfouCNMekueLMZentilinLTamgueOPefuraEWYet al. MicroRNA hsa-miR-29a-3p is a plasma biomarker for the differential diagnosis and monitoring of tuberculosis. Tuberculosis. (2019) 114:69–76. doi: 10.1016/j.tube.2018.12.001
33
Corral-FernándezNECortes-GarcíaJDBrunoRSRomano-MorenoSMedellín-GaribaySEMagaña-AquinoMet al. Analysis of transcription factors, microRNAs and cytokines involved in T lymphocyte differentiation in patients with tuberculosis after directly observed treatment short-course. Tuberculosis. (2017) 105:1–8. doi: 10.1016/j.tube.2017.03.007
34
WangCYangSLiuCMJiangTTChenZLTuHHet al. Screening and identification of four serum miRNAs as novel potential biomarkers for cured pulmonary tuberculosis. Tuberculosis. (2018) 108:26–34. doi: 10.1016/j.tube.2017.08.010
35
CuiJYLiangHWPanXLLiDJiaoNLiuYHet al. Characterization of a novel panel of plasma microRNAs that discriminates between Mycobacterium tuberculosis infection and healthy individuals. PloS One. (2017) 12:e0184113. doi: 10.1371/journal.pone.0184113
36
WangCLiuCMWeiLLShiLYPanZFMaoLGet al. A group of novel serum diagnostic biomarkers for multidrug-resistant tuberculosis by iTRAQ-2D LC-MS/MS and solexa sequencing. Int J Biol Sci. (2016) 12:246–56. doi: 10.7150/ijbs.13805
37
CarranzaCHerreraMTGuzmán-BeltránSSalgado-CantúMGSalido-GuadarramaISantiagoEet al. A Dual Marker for Monitoring MDR-TB Treatment: Host-Derived miRNAs and M. tuberculosis-Derived RNA Sequences in Serum. Front Immunol. (2021) 12:760468. doi: 10.3389/fimmu.2021.760468
38
SunWZhangXHeXZhangJWangXLinWet al. Long non-coding RNA SNHG16 silencing inhibits proliferation and inflammation in Mycobacterium tuberculosis-infected macrophages by targeting miR-140-5p expression. Infection Genet Evolution. (2022) 103:105325. doi: 10.1016/j.meegid.2022.105325
39
LiuGWanQLiJHuXGuXXuS. Silencing miR-125b-5p attenuates inflammatory response and apoptosis inhibition in mycobacterium tuberculosis-infected human macrophages by targeting DNA damage-regulated autophagy modulator 2 (DRAM2). Cell Cycle. (2020) 19:3182–94. doi: 10.1080/15384101.2020.1838792
40
TuHYangSJiangTWeiLShiLLiuCet al. Elevated pulmonary tuberculosis biomarker miR-423-5p plays critical role in the occurrence of active TB by inhibiting autophagosome-lysosome fusion. Emerg Microbes Infect. (2019) 8:448–60. doi: 10.1080/22221751.2019.1590129
41
YangJDanHChenYZouLLiuSWangFet al. miRNA differential expression profile analysis and identification of potential key genes in active tuberculosis. J Cell Mol Med. (2025) 29:e70567. doi: 10.1111/jcmm.70567
42
CuiXZhangFMengHYuanTLiMYuanDet al. Transport of miR-766–3p to A549 cells by plasma-derived exosomes and its effect on intracellular survival of Mycobacterium tuberculosis by regulating NRAMP1 expression in A549 cells. Microbiological Res. (2025) 290:127943. doi: 10.1016/j.micres.2024.127943
43
LiuJLiYLiuTShiYWangYWuJet al. Novel biomarker panel of let-7d-5p and miR-140-5p can distinguish latent tuberculosis infection from active tuberculosis patients. IDR. (2023) 16:3847–59. doi: 10.2147/IDR.S412116
44
SampathPMoorthyMMenonAMadhavLJanakiADhanapalMet al. Downregulation of monocyte miRNAs: implications for immune dysfunction and disease severity in drug-resistant tuberculosis. Front Immunol. (2023) 14:1197805. doi: 10.3389/fimmu.2023.1197805
45
ZhangHSunZWeiWLiuZFlemingJZhangSet al. Identification of serum microRNA biomarkers for tuberculosis using RNA-seq. PloS One. (2014) 9:e88909. doi: 10.1371/journal.pone.0088909
46
SpinelliSVDiazAD’AttilioLMarchesiniMMBogueCBayMLet al. Altered microRNA expression levels in mononuclear cells of patients with pulmonary and pleural tuberculosis and their relation with components of the immune response. Mol Immunol. (2013) 53:265–9. doi: 10.1016/j.molimm.2012.08.008
47
KameswaranVBramswigNCMcKennaLBPennMSchugJHandNJet al. Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. Cell Metab. (2014) 19:135–45. doi: 10.1016/j.cmet.2013.11.016
48
Fuentevilla-AlvarezGSotoMERobles-HerreraGJVargas-AlarcónGSámanoRMeza-ToledoSEet al. Analysis of circulating miRNA expression profiles in type 2 diabetes patients with diabetic foot complications. IJMS. (2024) 25:7078. doi: 10.3390/ijms25137078
49
KatayamaMWiklanderOPBFritzTCaidahlKEl-AndaloussiSZierathJRet al. Circulating exosomal miR-20b-5p is elevated in type 2 diabetes and could impair insulin action in human skeletal muscle. Diabetes. (2019) 68:515–26. doi: 10.2337/db18-0470
50
ShakerOGAbdelaleemOOMahmoudRHAbdelghaffarNKAhmedTISaidOMet al. Diagnostic and prognostic role of serum miR-20b, miR-17-3p, HOTAIR, and MALAT1 in diabetic retinopathy. IUBMB Life. (2019) 71:310–20. doi: 10.1002/iub.1970
51
WealeCJMatshaziDMDavidsSFGRaghubeerSErasmusRTKengneAPet al. MicroRNAs-1299, -126-3p and -30e-3p as potential diagnostic biomarkers for prediabetes. Diagnostics. (2021) 11:949. doi: 10.3390/diagnostics11060949
52
RouxMPerretCFeigerlovaEMohand OumoussaBSaulnierPJProustCet al. Plasma levels of hsa-miR-152-3p are associated with diabetic nephropathy in patients with type 2 diabetes. Nephrol Dialysis Transplantation. (2018) 33:2201–7. doi: 10.1093/ndt/gfx367
53
AliHMalikMZAbu-FarhaMAbubakerJCherianPAl-KhairiIet al. Dysregulated urinary extracellular vesicle small RNAs in diabetic nephropathy: implications for diagnosis and therapy. J Endocrine Soc. (2024) 8:bvae114. doi: 10.1210/jendso/bvae114
54
GrecoMChiefariEAccattatoFCoriglianoDMArcidiaconoBMirabelliMet al. MicroRNA-1281 as a novel circulating biomarker in patients with diabetic retinopathy. Front Endocrinol. (2020) 11:528. doi: 10.3389/fendo.2020.00528
55
RazaSTRizviSAfreenSSrivastavaSSiddiquiZFatimaNet al. Association of the circulating micro-RNAs with susceptible and newly diagnosed type 2 diabetes mellitus cases. Adv biomark Sci Technology. (2023) 5:57–67. doi: 10.1016/j.abst.2023.05.001
56
YangTTSongSJXueHBShiDFLiuCMLiuH. Regulatory T cells in the pathogenesis of type 2 diabetes mellitus retinopathy by miR-155. Eur Rev Med Pharmacol Sci. (2015) 19:2010–5.
57
BaiXLuoQTanKGuoL. Diagnostic value of VDBP and miR−155−5p in diabetic nephropathy and the correlation with urinary microalbumin. Exp Ther Med. (2020) 20:1–1. doi: 10.3892/etm.2020.9214
58
GuglielmiVD’AdamoMMenghiniRCardelliniMGentileschiPFedericiMet al. MicroRNA 21 is up-regulated in adipose tissue of obese diabetic subjects. Nutr Healthy Aging. (2017) 4:141–5. doi: 10.3233/NHA-160020
59
McClellandADHerman-EdelsteinMKomersRJhaJCWinbanksCEHagiwaraSet al. miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin Science. (2015) 129:1237–49. doi: 10.1042/CS20150427
60
MengXYuXLeiP. Clinical value of miR-23a-3p expression in early diagnosis of diabetic kidney disease. Endokrynol Pol. (2023). doi: 10.5603/EP.a2023.0057
61
Lozano-BartoloméJLlauradóGPortero-OtinMAltuna-CoyARojo-MartínezGVendrellJet al. Altered Expression of miR-181a-5p and miR-23a-3p Is Associated With Obesity and TNFα-Induced Insulin Resistance. J Clin Endocrinol Metab. (2018) 103:1447–58.
62
FangYSunSWuJLiuGWuQRanX. Alterations in the levels of urinary exosomal microRNA-183-5p and microRNA-125a-5p in individuals with type 2 diabetes mellitus. Biomedicines. (2024) 12:2608. doi: 10.3390/biomedicines12112608
63
YuGWangLGHanYHeQY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS: A J Integr Biol. (2012) 16:284–7. doi: 10.1089/omi.2011.0118
64
VlachosISZagganasKParaskevopoulouMDGeorgakilasGKaragkouniDVergoulisTet al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. (2015) 43:W460–6.
65
BarrySESawkaAMaldariAInauenJLaBroomeSGeakeJB. Macrophage dysfunction in tuberculosis–diabetes mellitus comorbidity: A scoping review of immune dysregulation and disease progression. Diabetology. (2025) 6:35. doi: 10.3390/diabetology6050035
66
SsekamattePSitendaDNabatanziRNkurunungiGNakibuuleMKibirigeDet al. Metabolic dysfunction impairs Mycobacterium tuberculosis-specific cytokine and chemokine responses in latent tuberculosis and type 2 diabetes mellitus. Sci Rep. (2025) 15:30474. doi: 10.1038/s41598-025-16385-8
67
QueirozATLVinhaesCLFukutaniERGupteANKumarNPFukutaniKFet al. A multi-center, prospective cohort study of whole blood gene expression in the tuberculosis-diabetes interaction. Sci Rep. (2023) 13:7769. doi: 10.1038/s41598-023-34847-9
68
Van DoornCLREckoldCRonacherKRuslamiRVan VeenSLeeJSet al. Transcriptional profiles predict treatment outcome in patients with tuberculosis and diabetes at diagnosis and at two weeks after initiation of anti-tuberculosis treatment. eBioMedicine. (2022) 82:104173. doi: 10.1016/j.ebiom.2022.104173
69
RochaEFVinhaesCLAraújo-PereiraMMotaTFGupteANKumarNPet al. The sound of silent RNA in tuberculosis and the lncRNA role on infection. iScience. (2024) 27:108662. doi: 10.1016/j.isci.2023.108662
70
LuYWangXDongHWangXYangPHanLet al. Bioinformatics analysis of microRNA expression between patients with and without latent tuberculosis infections. Exp Ther Med. (2019) 3977–88. doi: 10.3892/etm.2019.7424
71
SinigagliaAPetaERiccettiSVenkateswaranSManganelliRBarzonL. Tuberculosis-associated microRNAs: from pathogenesis to disease biomarkers. Cells. (2020) 9:2160. doi: 10.3390/cells9102160
72
HarapanHFitraFIchsanIMulyadiMMiottoPHasanNAet al. The roles of microRNAs on tuberculosis infection: Meaning or myth? Tuberculosis. (2013) 93:596–605. doi: 10.1016/j.tube.2013.08.004
73
MaBWangSWuWShanPChenYMengJet al. Mechanisms of circRNA/lncRNA-miRNA interactions and applications in disease and drug research. Biomedicine Pharmacotherapy. (2023) 162:114672. doi: 10.1016/j.biopha.2023.114672
74
DengXChuXWangPMaXWeiCSunCet al. MicroRNA-29a-3p reduces TNFα-induced endothelial dysfunction by targeting tumor necrosis factor receptor 1. Mol Ther Nucleic Acids. (2019) 18:903–15. doi: 10.1016/j.omtn.2019.10.014
75
FitrianaNIswantiFCSadikinM. The role of hypoxia-inducible factor in mycobacterium tuberculosis-infected macrophages. Mol Cell BioMed Sci. (2024) 8:23. doi: 10.21705/mcbs.v8i1.405
76
ArbuésASchmidigerSKammüllerMPortevinD. Extracellular matrix-induced GM-CSF and hypoxia promote immune control of mycobacterium tuberculosis in human in vitro granulomas. Front Immunol. (2021) 12:727508. doi: 10.3389/fimmu.2021.727508
77
QuallsJEMurrayPJ. Immunometabolism within the tuberculosis granuloma: amino acids, hypoxia, and cellular respiration. Semin Immunopathol. (2016) 38:139–52. doi: 10.1007/s00281-015-0534-0
78
ChengPWangLGongW. Cellular immunity of patients with tuberculosis combined with diabetes. J Immunol Res. (2022) 2022:6837745. doi: 10.1155/2022/6837745
79
Kumar NathellaPBabuS. Influence of diabetes mellitus on immunity to human tuberculosis. Immunology. (2017) 152:13–24. doi: 10.1111/imm.12762
80
Al-SayyarAHulmeKDThibautRBayryJSheedyFJShortKRet al. Respiratory tract infections in diabetes – lessons from tuberculosis and influenza to guide understanding of COVID-19 severity. Front Endocrinol. (2022) 13:919223. doi: 10.3389/fendo.2022.919223
81
YeZLiLYangLZhuangLAspatwarAWangLet al. Impact of diabetes mellitus on tuberculosis prevention, diagnosis, and treatment from an immunologic perspective. Exploration. (2024) 4:20230138. doi: 10.1002/EXP.20230138
82
AbbasUMasoodKIKhanAIrfanMSaifullahNJamilBet al. Tuberculosis and diabetes mellitus: Relating immune impact of co-morbidity with challenges in disease management in high burden countries. J Clin Tuberculosis Other Mycobacterial Diseases. (2022) 29:100343. doi: 10.1016/j.jctube.2022.100343
83
TeránGLiHCatrinaSBLiuRBrighentiSZhengXet al. High glucose and carbonyl stress impair HIF-1-regulated responses and the control of mycobacterium tuberculosis in macrophages. mBio. (2022) 13:e01086–22. doi: 10.1128/mbio.01086-22
84
KrupinskyKCMichaelCTNandaPMattilaJTKirschnerD. Distinguishing multiple roles of T cell and macrophage involvement in determining lymph node fates during Mycobacterium tuberculosis infection. Smith AM editor. PloS Comput Biol. (2025) 21:e1013033. doi: 10.1371/journal.pcbi.1013033
85
ThulaseedharanAJabbarPKNairSJayakumariCRemaSPPDasDVet al. Prevalence of adrenal insufficiency and adrenal morphology in treatment-naïve tuberculosis patients: A cross-sectional study from a high-burden region. Clin Endocrinology. (2025) 103:436–46. doi: 10.1111/cen.15282
86
MajiAMisraRKumar MondalAKumarDBajajDSinghalAet al. Expression profiling of lymph nodes in tuberculosis patients reveal inflammatory milieu at site of infection. Sci Rep. (2015) 5:15214. doi: 10.1038/srep15214
87
WangFHuangGShenLPengYShaWChenZWet al. Genetics and functional mechanisms of STAT3 polymorphisms in human tuberculosis. Front Cell Infect Microbiol. (2021) 11:669394. doi: 10.3389/fcimb.2021.669394
88
ChenMObasanmiGArmstrongDLaveryNJKissenpfennigALoisNet al. STAT3 activation in circulating myeloid-derived cells contributes to retinal microvascular dysfunction in diabetes. J Neuroinflammation. (2019) 16:138. doi: 10.1186/s12974-019-1533-1
89
WangXLinYLiangYYeYWangDTaiAet al. Phosphorylated STAT3 suppresses microRNA-19b/1281 to aggravate lung injury in mice with type 2 diabetes mellitus-associated pulmonary tuberculosis. J Cell Mol Medi. (2020) 24:13763–74. doi: 10.1111/jcmm.15954
90
SartiEDolléCWolfensbergerRKusejkoKRussenbergerDBredlSet al. c-Myc inhibits macrophage antimycobacterial response in Mycobacterium tuberculosis infection. Immunology. (2025). doi: 10.1101/2025.01.09.632095
91
BucşanANVeatchASinghDKAkterSGoldenNAKirkpatrickMet al. Response to hypoxia and the ensuing dysregulation of inflammation impacts mycobacterium tuberculosis pathogenicity. Am J Respir Crit Care Med. (2022) 206:94–104. doi: 10.1164/rccm.202112-2747OC
92
De Oliveira RezendeASabóiaRSDa CostaACDa Silva MonteiroDMPZagmignanASantiagoLÂMet al. Restricted activation of the NF-κB pathway in individuals with latent tuberculosis infection after HIF-1α Blockade. Biomedicines. (2022) 10:817. doi: 10.3390/biomedicines10040817
93
BravermanJSogiKMBenjaminDNomuraDKStanleySA. HIF-1α Is an essential mediator of IFN-γ–dependent immunity to mycobacterium tuberculosis. J Immunol. (2016) 197:1287–97. doi: 10.4049/jimmunol.1600266
94
KnightMStanleyS. HIF-1α as a central mediator of cellular resistance to intracellular pathogens. Curr Opin Immunol. (2019) 60:111–6. doi: 10.1016/j.coi.2019.05.005
95
QiuBYuanPDuXJinHDuJHuangY. Hypoxia inducible factor-1α is an important regulator of macrophage biology. Heliyon. (2023) 9:e17167. doi: 10.1016/j.heliyon.2023.e17167
96
Osada-OkaMGodaNSaigaHYamamotoMTakedaKOzekiYet al. Metabolic adaptation to glycolysis is a basic defense mechanism of macrophages for Mycobacterium tuberculosis infection. Int Immunol. (2019) 31:781–93. doi: 10.1093/intimm/dxz048
97
BeltonMBrilhaSManavakiRMauriFNijranKHongYTet al. Hypoxia and tissue destruction in pulmonary TB. Thorax. (2016) 71:1145–53. doi: 10.1136/thoraxjnl-2015-207402
98
Jurcic SmithKLLeeS. Inhibition of apoptosis by Rv2456c through Nuclear factor-κB extends the survival of Mycobacterium tuberculosis. Int J Mycobacteriology. (2016) 5:426–36. doi: 10.1016/j.ijmyco.2016.06.018
99
AgrawalPUpadhyayAKumarA. microRNA as biomarkers in tuberculosis: a new emerging molecular diagnostic solution. Diagn Microbiol Infect Disease. (2024) 108:116082. doi: 10.1016/j.diagmicrobio.2023.116082
100
PattnaikBPatnaikNMittalSMohanAAgrawalAGuleriaRet al. Micro RNAs as potential biomarkers in tuberculosis: A systematic review. Noncoding RNA Res. (2022) 7:16–26. doi: 10.1016/j.ncrna.2021.12.005
101
GunasekaranHSampathPThiruvengadamKMalaisamyMRamasamyRRanganathanUDet al. A systematic review and meta-analysis of circulating serum and plasma microRNAs in TB diagnosis. BMC Infect Dis. (2024) 24:402. doi: 10.1186/s12879-024-09232-0
102
Centre for Innovation Research and Development (CIRD)KulshresthaA. Expression and regulation of microRNAs in tuberculosis: A review. Int J Pure App Biosci. (2019) 7:329–40. Dr. B. Lal Institute of Biotechnology, Dr. B. Lal Clinical Laboratories Pvt. Ltd., Jaipur, 302017, India. doi: 10.18782/2320-7051.7726
103
MirzaeiRBabakhaniSAjorlooPAhmadiRHHosseini-FardSRKeyvaniHet al. The emerging role of exosomal miRNAs as a diagnostic and therapeutic biomarker in Mycobacterium tuberculosis infection. Mol Med. (2021) 27:34. doi: 10.1186/s10020-021-00296-1
104
LiXXuYLiaoP. Diagnostic performance of microRNA-29a in active pulmonary tuberculosis: a systematic review and meta-analysis. Clinics. (2023) 78:100290. doi: 10.1016/j.clinsp.2023.100290
105
WuZTanQJiaXWuHLiangJWenWet al. Single molecule measurements of microRNAs in the serum of patients with pulmonary tuberculosis. Front Immunol. (2024) 15:1418085. doi: 10.3389/fimmu.2024.1418085
106
HuaYSunFWuYHuangYZhouFZhangHet al. MicroRNA-155 from sputum as noninvasive biomarker for diagnosis of active pulmonary tuberculosis. Iranian J Basic Med Sci. (2020) 23:1–11. doi: 10.22038/ijbms.2020.44029.10324
107
HeJXiongJHuangY. miR-29 as diagnostic biomarkers for tuberculosis: a systematic review and meta-analysis. Front Public Health. (2024) 12:1384510. doi: 10.3389/fpubh.2024.1384510
108
ZhangTLvCLiLChenSLiuSWangCet al. Plasma miR-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals. BioMed Res Int. (2013) 2013:1–6. doi: 10.1155/2013/761617
109
ZeinaliFAghaei ZarchSMJahan-MihanAKalantarSMVahidi MehrjardiMYFallahzadehHet al. Circulating microRNA-122, microRNA-126-3p and microRNA-146a are associated with inflammation in patients with pre-diabetes and type 2 diabetes mellitus: A case control study. Rom S editor. PloS One. (2021) 16:e0251697. doi: 10.1371/journal.pone.0251697
110
ZhuHLeungSW. MicroRNA biomarkers of type 2 diabetes: evidence synthesis from meta-analyses and pathway modelling. Diabetologia. (2023) 66:288–99. doi: 10.1007/s00125-022-05809-z
111
SidorkiewiczINiemiraMMaliszewskaKErolABielskaASzalkowskaAet al. Circulating miRNAs as a predictive biomarker of the progression from prediabetes to diabetes: outcomes of a 5-year prospective observational study. JCM. (2020) 9:2184. doi: 10.3390/jcm9072184
112
Jiménez-LucenaRCamargoAAlcalá-DiazJFRomero-BaldonadoCLuqueRMVan OmmenBet al. A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study. Exp Mol Med. (2018) 50:1–12. doi: 10.1038/s12276-018-0194-y
113
Jiménez-LucenaRRangel-ZúñigaOAAlcalá-DíazJFLópez-MorenoJRoncero-RamosIMolina-AbrilHet al. Circulating miRNAs as predictive biomarkers of type 2 diabetes mellitus development in coronary heart disease patients from the CORDIOPREV study. Mol Ther Nucleic Acids. (2018) 12:146–57. doi: 10.1016/j.omtn.2018.05.002
114
JaegerAZollingerLSaelyCHMuendleinAEvangelakosINasiasDet al. Circulating microRNAs -192 and -194 are associated with the presence and incidence of diabetes mellitus. Sci Rep. (2018) 8:14274. doi: 10.1038/s41598-018-32274-9
115
HawezAAl-HaidariAMadhiRRahmanMThorlaciusH. MiR-155 regulates PAD4-dependent formation of neutrophil extracellular traps. Front Immunol. (2019) 10:2462. doi: 10.3389/fimmu.2019.02462
116
ZlatarLKnopfJSinghJWangHMuñoz-BecerraMHerrmannIet al. Neutrophil extracellular traps characterize caseating granulomas. Cell Death Dis. (2024) 15:548. doi: 10.1038/s41419-024-06892-3
117
HarriesADSatyanarayanaSKumarAMVNagarajaSBIsaakidisPMalhotraSet al. Epidemiology and interaction of diabetes mellitus and tuberculosis and challenges for care: a review. Public Health Action. (2013) 3:S3–9. doi: 10.5588/pha.13.0024
118
CritchleyJARestrepoBIRonacherKKapurABremerAASchlesingerLSet al. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes. Chest. (2017) 152:165–73. doi: 10.1016/j.chest.2017.04.155
119
HarriesADKumarAMVSatyanarayanaSLinYZachariahRLönnrothKet al. Diabetes mellitus and tuberculosis: programmatic management issues. Int J Tuberc Lung Dis. (2015) 19:879–86. doi: 10.5588/ijtld.15.0069
120
HarriesADMurrayMBJeonCYOttmaniSELonnrothKBarretoMLet al. Defining the research agenda to reduce the joint burden of disease from Diabetes mellitus and Tuberculosis: Research to reduce the joint burden of diabetes and tuberculosis. Trop Med Int Health. (2010) 15:659–63. doi: 10.1111/j.1365-3156.2010.02523.x
121
ZhaoLFanKSunXLiWQinFShiLet al. Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus. Front Immunol. (2024) 14:1305325. doi: 10.3389/fimmu.2023.1305325
122
LiangQJinWHuangZYinHLiuSLiuLet al. A plasma 3-marker microRNA biosignature distinguishes spinal tuberculosis from other spinal destructive diseases and pulmonary tuberculosis. Front Cell Infect Microbiol. (2023) 13:1125946. doi: 10.3389/fcimb.2023.1125946
123
WangJZhuXXiongXGePLiuHRenNet al. Identification of potential urine proteins and microRNA biomarkers for the diagnosis of pulmonary tuberculosis patients. Emerging Microbes Infections. (2018) 7:1–13. doi: 10.1038/s41426-018-0066-5
124
MoorthySBhaskarESinghSSilambananS. Diagnostic utility of microRNA profiles in cavitatory and non-cavitatory pulmonary tuberculosis: Research protocol. World J Exp Med. (2025) 15:1–8. Available online at: https://www.wjgnet.com/2220-315X/full/v15/i1/97460.htm.
125
UeberbergBKohnsMMayatepekEJacobsenM. Are microRNAs suitable biomarkers of immunity to tuberculosis? Mol Cell Pediatr. (2014) 1:8. doi: 10.1186/s40348-014-0008-9
126
BarrySEChanBEllisMYangYPlitMLGuanGet al. Identification of miR-93 as a suitable miR for normalizing miRNA in plasma of tuberculosis patients. J Cell Mol Medi. (2015) 19:1606–13. doi: 10.1111/jcmm.12535
127
XinHCaoXDuYYanJHeRLiuZet al. The association between circulating microRNAs and the risk of active disease development from latent tuberculosis infection: a nested case-control study. Zhang L editor. Microbiol Spectr. (2022) 10:e02625–21. doi: 10.1128/spectrum.02625-21
128
FalzonDTimimiHKurosinskiPMiglioriGBVan GemertWDenkingerCet al. Digital health for the End TB Strategy: developing priority products and making them work. Eur Respir J. (2016) 48:29–45. doi: 10.1183/13993003.00424-2016
Summary
Keywords
bioinformatic analysis, biomarkers, microRNAs, systematic review, tuberculosis, type 2 diabetes mellitus
Citation
Chávez-Domínguez RL, Viettri M, Torres M, Corona-Galvan IA, Hernández-Diego E, Castañón-Arreola M and Carranza C (2026) Type 2 diabetes mellitus associated microRNAs in tuberculosis susceptibility: a systematic review and bioinformatic analysis. Front. Endocrinol. 17:1760933. doi: 10.3389/fendo.2026.1760933
Received
04 December 2025
Revised
06 January 2026
Accepted
12 January 2026
Published
23 February 2026
Volume
17 - 2026
Edited by
Nirali Rathwa, MaRS Discovery District, Canada
Updates
Copyright
© 2026 Chávez-Domínguez, Viettri, Torres, Corona-Galvan, Hernández-Diego, Castañón-Arreola and Carranza.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Claudia Carranza, carranza.salazar.claudia@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.